Product Code: ETC6182454 | Publication Date: Sep 2024 | Updated Date: May 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australias herpes zoster market is shaped by the increasing incidence of shingles, particularly among the elderly. The market benefits from the availability of effective vaccines and antiviral medications. Public health initiatives promoting vaccination and early diagnosis play a critical role in driving demand for preventive and therapeutic options in the country.
The Australian herpes zoster (shingles) market is growing due to the increasing incidence among older adults. With the government recommending and subsidizing vaccination (e.g., Shingrix), there is a growing focus on preventive care. Pharmaceutical firms are also expanding treatment offerings to manage postherpetic neuralgia.
The Australia Herpes Zoster Market faces challenges related to the underutilization of vaccines, particularly the shingles vaccine, which is recommended for older adults. Despite the availability of effective vaccines, there is a lack of widespread public awareness about the risk of herpes zoster (shingles), leading to lower vaccination rates. Furthermore, there is a challenge in providing timely treatment for individuals who develop shingles, as antiviral treatments are most effective when started early. The market also faces issues related to the cost and accessibility of vaccines and treatments, particularly for vulnerable populations who may have limited access to healthcare services.
The increasing uptake of vaccines and treatments for herpes zoster (shingles) in Australia is driven by an aging demographic. Investors can tap into pharmaceutical R&D, vaccine distribution logistics, and educational campaigns that boost awareness and vaccine uptake.
Vaccination policies under the National Immunisation Program (NIP) play a major role in the herpes zoster market. The government funds zoster vaccines for eligible age groups, thereby stimulating demand and ensuring disease prevention. The TGA monitors vaccine safety and efficacy, and public health campaigns help increase awareness and vaccine uptake.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Herpes Zoster Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Herpes Zoster Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Herpes Zoster Market - Industry Life Cycle |
3.4 Australia Herpes Zoster Market - Porter's Five Forces |
3.5 Australia Herpes Zoster Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.6 Australia Herpes Zoster Market Revenues & Volume Share, By Treatment and Prevention, 2021 & 2031F |
3.7 Australia Herpes Zoster Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Australia Herpes Zoster Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Australia Herpes Zoster Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Herpes Zoster Market Trends |
6 Australia Herpes Zoster Market, By Types |
6.1 Australia Herpes Zoster Market, By Diagnosis |
6.1.1 Overview and Analysis |
6.1.2 Australia Herpes Zoster Market Revenues & Volume, By Diagnosis, 2021- 2031F |
6.1.3 Australia Herpes Zoster Market Revenues & Volume, By Laboratory Testing, 2021- 2031F |
6.1.4 Australia Herpes Zoster Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Herpes Zoster Market, By Treatment and Prevention |
6.2.1 Overview and Analysis |
6.2.2 Australia Herpes Zoster Market Revenues & Volume, By Antiviral Medications, 2021- 2031F |
6.2.3 Australia Herpes Zoster Market Revenues & Volume, By Narcotic Medications, 2021- 2031F |
6.2.4 Australia Herpes Zoster Market Revenues & Volume, By Anti-Inflammatory Medications, 2021- 2031F |
6.2.5 Australia Herpes Zoster Market Revenues & Volume, By Antihistamines, 2021- 2031F |
6.2.6 Australia Herpes Zoster Market Revenues & Volume, By Anticonvulsants, 2021- 2031F |
6.2.7 Australia Herpes Zoster Market Revenues & Volume, By Capsaicin, 2021- 2031F |
6.2.8 Australia Herpes Zoster Market Revenues & Volume, By Others, 2021- 2031F |
6.2.9 Australia Herpes Zoster Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Herpes Zoster Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Australia Herpes Zoster Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Australia Herpes Zoster Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 Australia Herpes Zoster Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Herpes Zoster Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Australia Herpes Zoster Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.4.3 Australia Herpes Zoster Market Revenues & Volume, By Diagnostic Centers, 2021- 2031F |
6.4.4 Australia Herpes Zoster Market Revenues & Volume, By Research & Academic Institutes, 2021- 2031F |
6.4.5 Australia Herpes Zoster Market Revenues & Volume, By Home Care Settings, 2021- 2031F |
6.4.6 Australia Herpes Zoster Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Herpes Zoster Market Import-Export Trade Statistics |
7.1 Australia Herpes Zoster Market Export to Major Countries |
7.2 Australia Herpes Zoster Market Imports from Major Countries |
8 Australia Herpes Zoster Market Key Performance Indicators |
9 Australia Herpes Zoster Market - Opportunity Assessment |
9.1 Australia Herpes Zoster Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.2 Australia Herpes Zoster Market Opportunity Assessment, By Treatment and Prevention, 2021 & 2031F |
9.3 Australia Herpes Zoster Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Australia Herpes Zoster Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Australia Herpes Zoster Market - Competitive Landscape |
10.1 Australia Herpes Zoster Market Revenue Share, By Companies, 2024 |
10.2 Australia Herpes Zoster Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |